Axitinib in Metastatic Renal Cell Carcinoma

Targeted agents have revolutionized the management of metastatic renal cell carcinoma (RCC). Axitinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR), has been an important addition to currently available therapies for advanced RCC. Its ability to inhibit VEGFRs at nanomolar con...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittal, Kriti, Wood, Laura S., Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873008/
https://www.ncbi.nlm.nih.gov/pubmed/24392298
http://dx.doi.org/10.1007/s13554-012-0005-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873008/
https://www.ncbi.nlm.nih.gov/pubmed/24392298
http://dx.doi.org/10.1007/s13554-012-0005-2

Ejemplares similares